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Column in Hypertension
Comparative effectiveness and safety of empagliflozin on 
cardiovascular mortality and morbidity in adults with type 2 
diabetes
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Background: Based on a single placebo-controlled randomized clinical trial, empagliflozin is licensed to 
reduce cardiovascular death in diabetes and comorbid cardiovascular disease.
Methods: We examined the comparative effectiveness of empagliflozin on mortality and cardiovascular 
morbidity in type 2 diabetes. We conducted random-effects direct frequentist meta-analyses of aggregate 
data and appraised the quality of evidence using the Grading of Recommendations Assessment, Development 
and Evaluation (GRADE) methodology. Our search in PubMed, EMBASE, the Cochrane Library, 
clinicaltrials.gov, and PharmaPendium up to May 2017 identified 11 meta-analyses, multiple publications, 
and unpublished data from 29 randomized controlled trials (RCTs).
Results: Empagliflozin reduces all-cause mortality [relative risk (RR) of death, 0.69; 95% confidence 
interval (CI): 0.58–0.82; number needed to treat (NNT) to postpone mortality in one patient, 39; 95% CI: 
26–79; 1 RCT of 7,020 patients) in patients with but not without (RR, 0.90; 95% CI: 0.36–2.23; 14 RCTs 
of 7,707 patients) established cardiovascular disease when compared with placebo. Empagliflozin reduces 
cardiovascular mortality (RR, 0.62; 95% CI: 0.50–0.78; NNT, 45; 95% CI: 30–90; 1 RCT of 7,020 patients) 
in patients with but not without (RR, 0.98; 95% CI: 0.29–3.33; 10 RCTs of 5,429 patients) established 
cardiovascular disease when compared with placebo. There are no differences in cardiovascular morbidity 
and mortality and all-cause mortality between empagliflozin and metformin (4 RCTs of 1,344 patients), 
glimepiride (1 RCT of 1,549 patients), linagliptin (2 RCTs of 1,348 patients), or sitagliptin (3 RCTs of 1,483 
patients). Two network meta-analyses concluded that sodium-glucose cotransporter 2 (SGLT2) inhibitors, 
mostly due to empagliflozin, decrease all-cause and cardiovascular mortality but increase the risk of nonfatal 
stroke, genital infection, and volume depletion.
Conclusions: We conclude that empagliflozin reduces all-cause and cardiovascular mortality in patients 
with established cardiovascular disease and type 2 diabetes. Sparse direct evidence suggests no difference 
in mortality between empagliflozin and metformin, glimepiride, linagliptin, or sitagliptin. Long-term 
comparative safety needs to be established.
Keywords: Quality of evidence; type 2 diabetes; cardiovascular morbidity; all-cause mortality; cardiovascular 
mortality; empagliflozin; metformin; glimepiride; linagliptin; sitagliptin
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Introduction
One of the main goals in managing type 2 diabetes in adults 
is prevention of cardiovascular morbidity and mortality (1,2). 
Only a few of the available diabetes medications have shown 
benefits in reducing cardiovascular risks; most available drug 
classes such as thiazolidinediones, sulfonylureas, dipeptidyl 
peptidase-4 (DPP-4) inhibitors, and sodium-glucose 
cotransporter 2 (SGLT2) inhibitors have been approved 
based on their ability to decrease glycosylated hemoglobin 
A1c (HbA1c) rather than their ability to prevent morbidity 
and mortality (3,4). Network meta-analyses of SGLT2 
inhibitors suggest lower risk of all-cause and cardiovascular 
mortality from 3 oral SGLT2 inhibitors combined, at the 
expense of higher risk of nonfatal stroke [pooled relative 
risk (RR) 1.30; 95% confidence interval (CI): 1–1.68], 
genital infection (pooled RR 4.75; 95% CI: 4.00–5.63), and 
volume depletion (pooled RR 1.53; 95% CI: 1.27–1.83) 
(5,6). However, the reduction in the risk of mortality and 
morbidity is mostly attributable to one drug, empagliflozin, 
the only drug approved by the FDA in 2016 to reduce the 
risk of cardiovascular death in adult patients with type 2 
diabetes mellitus and established cardiovascular disease (5,6).
Older meta-analyses focused on intermediate outcomes 
of empagliflozin when compared with placebo; e.g., HbA1c, 
blood pressure, and body weight (7-15). The most recent 
high-quality meta-analyses included 13 (6) and 16 (5) 
randomized controlled trials (RCTs) that reported mortality 
and morbidity in adults with type 2 diabetes treated 
with empagliflozin but did not examine the comparative 
effectiveness of empagliflozin and other specific antidiabetic 
drugs (5,6). Clinicians have to select specific drugs for 
individual patients rather than relying on drug class benefits 
and harms.
To support clinical decisions at point of care with 
all available evidence, we conducted a rapid review of 
the published and unpublished data from the recently 
completed RCTs, meta-analyses of RCTs, and primary 
observational studies that compared the effects of 
empagliflozin with those of other antidiabetic drugs on all-
cause and cardiovascular mortality and morbidity.
Methods
We used a standard recommended methodology in 
conducting systematic literature reviews and meta-analyses 
from the Cochrane Collaboration and the Agency for 
Healthcare Research and Quality (16,17). We developed a 
priori protocol for a systematic literature review to answer 
the clinical question about the efficacy and comparative 
effectiveness of empagliflozin and other antidiabetic 
medications against mortality and cardiovascular morbidity 
in adults with type 2 diabetes.
We defined the target population as adults with type 2 
diabetes. Eligible interventions included SGLT2 inhibitor 
empagliflozin when compared with placebo or other 
antidiabetic medications. Eligible outcomes included all-
cause and underlying cause-specific mortality, myocardial 
infarction (MI), stroke, incidence or progression of heart 
failure, and hospitalizations for major cardiovascular events. 
Intermediate outcomes included diabetes control as HbA1c 
<7% or as defined in the primary studies. We reviewed the 
frequency and severity of hypoglycemia as well as any harms 
from examined treatments.
We conducted a comprehensive search in PubMed, 
EMBASE, the Cochrane Library, www.clinicaltrials.gov 
and PharmaPendium (www.pharmapendium.com) up 
to May 2017 to find systematic reviews, published and 
unpublished RCTs, and nationally representative controlled 
observational studies that reported adjusted effect estimates 
(16,17). All of the authors determined the studies’ eligibility. 
All citations found during the searches are stored in a 
reference database.
The data was extracted from the Clinical Trials 
Transformation Initiative (CTTI) (https://www.ctti-
clinicaltrials.org/aact-database), checked for quality, 
and stored in the HPCC platform (High-Performance 
Computing Cluster, https://hpccsystems.com/).
We performed direct frequentist meta-analyses of 
aggregate data when definitions of the active and control 
intervention and patient outcomes were deemed similar 
for pooling (18). We used random effects models to 
address inevitable differences in patient characteristics 
across primary RCTs. For each abstracted hypothesis, we 
calculated absolute risk difference and RR with 95% CI. 
We calculated number needed to treat (NNT) and number 
of attributable events per 1,000 treated with 95% CI based 
on statistically significant differences in absolute risks of 
the outcomes. We examined consistency in results across 
studies with chi-square tests and I2 statistics and concluded 
statistically significant heterogeneity if I2 was >50% (16). 
Statistically significant heterogeneity did not preclude 
statistical pooling (18). However, we planned exploring 
heterogeneity with a priori defined patient characteristics, 
drug doses, and study quality if this information was 
available in the studies (18).
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We used consensus method guidelines for systematic 
review and meta-analyses that do not recommend 
conducting post hoc analyses of statistical power (19-22). 
Instead, we downgraded our confidence in true treatment 
effects based on calculated optimal information size as the 
number of patients required for an adequately powered 
individual trial (23). Since power is more closely related 
to number of events than to sample size, we concluded 
imprecision in treatment effects if fewer than 250 patients 
experienced the event (23).
We used Statistics/Data Analysis, STATA software 
(StataCorp LP, College Station, Texas). Statistical 
significance was evaluated at a 95% confidence level.
We evaluated the quality of systematic reviews using the 
Assessment of Multiple Systematic Reviews (AMSTAR) (24). 
For primary RCTs, we used the Cochrane risk of bias tool 
on a 3-point scale: high bias, low bias, and unclear (25,26). 
A low risk of bias was assumed when RCTs met all the risk-
of-bias criteria, a medium risk of bias if at least 1 of the risk-
of-bias criteria was not met, and a high risk of bias if 2 or 
more risk-of-bias criteria were not met. An unknown risk 
of bias was assigned for the studies with poorly reported 
risk-of-bias criteria. We assigned high risk of bias to all 
observational studies.
The authors assigned the quality of evidence ratings as 
high, moderate, low, or very low, according to risk of bias in 
the body of evidence, directness of comparisons, precision 
and consistency in treatment effects, and the evidence 
of reporting bias, using Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
methodology (27).
A high quality of evidence was assigned to well-designed 
RCTs with consistent findings. The quality of evidence 
was downgraded to moderate if at least 1 of 4 quality of 
evidence criteria was not met; for example, moderate quality 
of evidence was assigned if there was a high risk of bias in 
the body of evidence or if the results were not consistent 
or precise. The quality of evidence was downgraded to low 
if 2 or more criteria were not met. We concluded a high 
risk of bias in the body of evidence if at least one RCT had 
high risk of bias. We downgraded the quality of evidence 
when we suspected high risk of publication bias due to 
unavailability of the results in clinicaltrials.gov or journal 
articles.
A low quality of evidence was assigned to nonrandomized 
studies, but the rating was upgraded if there was a 
strong or dose-response association (28). Evidence was 
defined as insufficient when no studies provided valid 
information about treatment effects. This approach was 
applied regardless of whether the results were statistically 
significant.
Results
Our comprehensive search in PubMed, EMBASE, the 
Cochrane Library, and clinicaltrials.gov up to May 2017 
identified 11 meta-analyses, multiple publications as well as 
unpublished data from 29 RCTs, and one non-randomized 
study that examined the benefits and harms of empagliflozin 
in people with type 2 diabetes (5-14,29). We also identified 
2 high-quality meta-analyses and multiple publications 
as well as unpublished data from 9 RCTs that directly 
compared empagliflozin with other antidiabetic drugs in 
people with type 2 diabetes (5-7,30-48).
Primary studies enrolled adults with type 2 diabetes and 
various baseline degrees of cardiovascular risk, permitted 
administration of metformin and other antidiabetic drugs, 
and aimed mostly at diabetes control and drug safety. 
Only one large non-inferiority trial, the EMPA-REG 
OUTCOME trial, was designed to examine difference 
in a composite outcome defined as the first occurrence of 
cardiovascular death, nonfatal MI, or nonfatal stroke in 
adults with type 2 diabetes and high cardiovascular risk (49).
Efficacy
Moderate-quality evidence suggests that empagliflozin 
reduces all-cause mortality (7,11,40,44,46,47,49-61) and 
increases the rates of diabetes control without increasing 
the risk of serious adverse effects and hypoglycemia when 
compared with placebo in adults with type 2 diabetes 
(Table 1) (50,51,70). The increase in rates of glycemic 
improvement starts at the dose of 10 mg/day (150 
attributable events per 1,000 treated, Figure 1) and increases 
to 210 attributable events per 1,000 treated after the larger 
dose of empagliflozin (25 mg/day, Figure 1).
Low-quality evidence suggests that empagliflozin reduces 
cardiovascular mortality, the risk of hospitalization for any 
cause (73), and hospitalizations for heart failure (59), as well 
as the risk of developing heart failure (73), developing or 
worsening of nephropathy (58), and the risk of treatment 
discontinuation due to lack of efficacy, at the expense of 
higher risk of adverse effects (Table 1) (7,11,40,44,46,47,49-
61,70,75-77). The observed improvement in patient 
outcomes is attributable to the largest RCT, EMPA-REG 
OUTCOME, which enrolled patients with established 
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cardiovascular diseases (59). Sensitivity analyses excluding 
this RCT demonstrate no protective effects from 
empagliflozin against all-cause and cardiovascular mortality 
in all other RCTs combined (Table 1). There are no 
differences in the risk of stroke or coronary events between 
empagliflozin and placebo (Table 1) (40,44,49-59,61,70).
Subgroup analysis of the EMPA-REG OUTCOME trial 
demonstrates that empagliflozin is better than placebo in 
reducing the risk of major cardiovascular events in older 
patients and adults with HbA1c 7.0–8.5% (P value for 
interaction <0.05, Table S1). Baseline heart failure does not 
modify empagliflozin effects on cardiovascular mortality and 
the risk of major cardiovascular effects (data not shown) (73). 
Empagliflozin is not better than placebo in adults with BMI 
≥30 kg/m2 (P value for interaction 0.06, Table S1).
Safety analyses demonstrate that empagliflozin increases 
the risk of genital infection, thirst, and polyuria and reduces 
the risk of acute renal injury and failure, hypertension, and 
worsening of heart failure (Table S2) (7,11,31,40,50,51,53-
56,58,59,62-67,77,78,81-83). Empagliflozin’s safety profile 
is similar in patients with normal and impaired baseline 
renal function (Table S2).
Post-marketing surveillance suggests more than 1900 
case reports of various adverse effects, including fungal and 
urinary tract infections, diabetic ketoacidosis, unintentional 
weight loss, pollakiuria, dizziness, dehydration, nausea, and 
vomiting reported by patients taking empagliflozin among 
other drugs for type 2 diabetes (Table S3). In addition, 
the European Medicines Agency recently requested that 
information on potential risk of toe amputation be included 
in prescribing information for all SGLT2 inhibitors (84).
Comparative effectiveness
Low-quality evidence suggests that there are no differences 
in mortality, morbidity, diabetes control, and serious 
adverse effects between empagliflozin and metformin 
(Table 2) (5,31,33,34,37,39,43,46-48,81). Empagliflozin 
reduces the risk of total non-serious adverse effects when 
compared with metformin, with 51 avoided adverse events 
per 1,000 treated (Table 2) (5,31,33,34,37,39,43,46-48,81).
Very low-quality evidence from a single RCT suggests that 
empagliflozin decreases HbA1c, the risk of hypoglycemia, 
and total non-serious adverse effects when compared with 
glimepiride, at the expense of higher cumulative risk of total 
combined serious adverse effects (Table 3) (36,42,45). There 
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Figure 1 Diabetes control (HbA1c <7%) after different doses of empagliflozin when compared with placebo (random effects meta-analysis 
of randomized trials of adults with type 2 diabetes). RD, absolute risk difference. 
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Table 2 Empagliflozin versus metformin in adults with type 2 diabetes
Outcomes 
Risk with intervention 
per 1,000 
Risk with comparator per 1,000, 
attributable avoided events per 
1,000 treated [95% CI]
Relative measure of 
association (95% CI)
Number of participants (studies); 
quality of evidence (GRADE)




0 0 RR inestimable 1,073 (3 RCT) (5,31,34,37,46-48); low
Myocardial infarction 5 1 RR 1.18 (0.31–4.58) 2,024 (5 RCTs) 
(5,31,33,34,37,39,43,46-48); low
Stroke 1 3 RR 0.54 (0.09–3.08) 2,024 (5 RCTs) 
(5,31,33,34,37,39,43,46-48); low
HbA1c <7.0% 331 390 RR 0.85 (0.66–1.10) 539 (2 RCTs) (31,33,43); low
Hypoglycemia 10 15 RR 0.55 (0.13–2.41) 1,290 (3 RCTs) (33,37,43,48,81); low
Total, non-serious 
adverse effects
214 262, 48 [5–92] RR 0.80 (0.64–0.99), 
NNTp 21 [11–200]
1,614 (3 RCTs) (31,33,43,81); low‡
Total, serious 
adverse events
26 25 RR 0.80 (0.39–1.63) 1,532 (3 RCTs) (31,33,43,81); low
Population: adults with uncontrolled type 2 diabetes (7%≤ HbA1c ≤10%); settings: outpatient; intervention: empagliflozin, any dose, 
orally, once daily; comparator: metformin (500–1,000 mg twice daily). Attributable events per 1,000 are treated as the number of excessive 
or avoided events per 1,000 treated that are attributed to active treatment; attributable events per 1,000 treated are calculated as 
absolute rate difference multiplied by 1,000. ‡, favors empagliflozin. HbA1c, hemoglobin A1c; CI, confidence interval; GRADE, Grading of 
Recommendations Assessment, Development and Evaluation; NNTp, number needed to treat to prevent an outcome in one patient (when 
the outcome is more probable with control intervention); RCT, randomized controlled trial; RR, relative risk.
are no differences in any specific serious harms between 
empagliflozin and glimepiride (data not shown).
Low-quality evidence suggests that there are no differences 
in mortality, morbidity, and serious adverse effects between 
empagliflozin and linagliptin (Table 4) (5,34,35,46,47). 
Empagliflozin decreases HbA1c and the risk of total non-
serious adverse effects (Table 4) (5,34,35,46,47). Low-quality 
evidence suggests that there are no differences in mortality, 
morbidity, and total adverse effects between empagliflozin 
and sitagliptin (Table 5) (5,32,33,38,40,43,44).
Specific adverse effects differ among examined drugs, 
according to the labeling information (Table S4). These 
differences should be taken into account when selecting 
specific drugs for patients with higher baseline risk of 
specific harms. Combined drug formulations would likely 
result in a cumulative increase in the risk of specific adverse 
effects.
Post-marketing surveillance suggests that lactic acidosis 
(6,754 cases), diarrhea (3,774 cases), and acute renal 
failure (3,754 cases) are the most common adverse effects 
reported in patients taking metformin among other drugs 
for type 2 diabetes (Table S3). Hypoglycemia (675 cases), 
hypoglycemic coma (142 cases), and acute renal failure 
(126 cases) are the most common adverse effects reported 
in patients taking glimepiride among other drugs for type 
2 diabetes (Table S3). Pancreatitis (328 cases), nausea (216 
cases), and rash (178 cases) are the most common adverse 
effects reported in patients taking linagliptin among other 
drugs for type 2 diabetes (Table S3). Pancreatitis (2,459 
cases), pancreatic carcinoma (1,604 cases), diarrhea (1,175 
cases), nausea (1,175 cases), and hypoglycemia (1,163 cases) 
are the most common adverse effects reported in patients 
taking sitagliptin among other drugs for type 2 diabetes 
(Table S3).
Discussion
Our findings that empagliflozin decreases overall and 
cardiovascular mortality are in concordance with high-
quality meta-analyses (5,6). The results are applicable 
to predominantly white adults with HbA1c 7–10% and 
established cardiovascular disease. Although the tests for 
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statistical interaction were not significant, ethnic and gender 
differences in drug benefits need further investigation. 
Previously published network meta-analyses also suggest 
that empagliflozin has a favorable benefits-to-harm profile, 
because it decreases HbA1c and arterial blood pressure 
without increased risk of hypoglycemia or weight gain (9,85). 
The evidence regarding the effects of empagliflozin on 
quality of life and the long-term safety of empagliflozin is 
insufficient.
Our review also found low-quality evidence that all-cause 
and cardiovascular mortality and morbidity are comparable 
after empagliflozin when compared with metformin, 
glimepiride, linagliptin, or sitagliptin in adults with type 
2 diabetes. We downgraded the quality of evidence due 
to risk of bias in the body of evidence and small number 
of events in RCTs. We also concluded reporting bias, 
because reporting of patient morbidity and specific adverse 
effects was inconsistent across studies, and the results 
of several completed studies were not available for the 
analysis. None of the head-to-head RCTs were powered 
to detect differences in mortality and morbidity. A single 
RCT suggested reduction in mortality and cardiovascular 
morbidity after empagliflozin when compared with placebo 
in adults with established cardiovascular disorder (58,59,68). 
This pivotal RCT provided only indirect comparative 
evidence that empagliflozin may be a drug of choice in 
people with type 2 diabetes and comorbid cardiovascular 
disorder (58,59,68).
The direct evidence regarding the comparative 
effectiveness of empagliflozin and other antidiabetic drugs 
including other SGLT2 inhibitors is insufficient. A recent 
single RCT demonstrated that injectable liraglutide reduces 
the risk of major cardiovascular events [hazard ratio (HR) 
0.87; 95% CI: 0.78–0.97] and all-cause mortality (HR 
0.85; 95% CI: 0.74–0.97) in adults with type 2 diabetes and 
high cardiovascular risk when compared with placebo (86). 
Although the RR reduction is larger with empagliflozin, 
well-designed direct RCTs are needed to conclude the 
comparative effectiveness of the 2 drugs. Previously 
published network meta-analyses of intermediate outcomes 
also suggest that empagliflozin has a favorable benefits-to-
harms profile, because it decreases HbA1c without increased 
risk of hypoglycemia or weight gain (9,15,85).
Our rapid review has several limitations. We did not 
contact drug manufacturers or principal investigators 
regarding unpublished or missing data. We do not know 
how many unregistered, unpublished studies have been 
conducted. We found no observational studies that provide 
adjusted for confounding estimates of the comparative 
effectiveness and safety of empagliflozin and other 
antidiabetic drugs.
Evidence-based guidelines recommend SGLT2 inhibitors 
among other available drug classes for adults with type 2 
diabetes who could not control diabetes with behavioral 
changes and metformin (1,2,4). A British guideline based 
on comprehensive evidence specifies that empagliflozin in 
combination with metformin should be recommended only 
to patients who cannot tolerate sulfonylureas or have a high 
risk of hypoglycemia or its consequences (3).
Future research should examine the long-term 
comparative benefits and harms of empagliflozin and other 
drug choices in patient subpopulations by demographics, 
comorbidities, and concomitant treatments.
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Supplementary
Table S1 Composite outcome of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke after empagliflozin versus placebo in subgroups of adults with type 2 diabetes and established cardiovascular disease
Outcomes Risk with intervention per 1,000 
Risk with comparator per 1,000, attributable avoided events per 1,000 
treated [95% CI]
Relative measure of association (95% CI)
Number of participants (studies); quality of 
evidence (GRADE)
Age (years)
<65 97 93 RR 1.04 (0.84–1.27), HR 1.04 (0.84–1.29) 3,893 (1 RCT) (59); low
≥65 114 155, 41 [15–67] RR 0.74 (0.61–0.89), NNTp 24 [15–66], HR 
0.71 (0.59–0.87)
3,127 (1 RCT) (59); very low‡
Sex
Male 110 126 RR 0.87 (0.74–1.02), HR 0.87 (0.73–1.02) 5,016 (1 RCT) (59); low
Female 91 107 RR 0.85 (0.64–1.12), HR 0.83 (0.62–1.11) 2,004 (1 RCT) (59); very low
Race
White 108 122 RR 0.88 (0.75–1.03), HR 0.88 (0.74–1.04) 5,081 (1 RCT) (59); low
Asian 79 114, 35 [3–67] RR 0.69 (0.50–0.95), NNTp 29 [15–352], 
HR 0.68 (0.48–0.95)
1,517 (1 RCT) (59); very low‡
Black/African-American 165 117 RR 1.41 (0.80–2.49), HR 1.48 (0.80–2.72) 357 (1 RCT) (59); very low
Hispanic/Latino 83 124, 42 [5–78] RR 0.66 (0.47–0.93), NNTp 24 [13–197], 
HR 0.63 (0.44–0.90)
1,265 (1 RCT) (59); very low‡
Not Hispanic/Latino 110 120 RR 0.91 (0.78–1.06), HR 0.91 (0.77–1.07) 5,747 (1 RCT) (59); low
Location
Europe 117 117 RR 1.00 (0.81–1.24), HR 1.02 (0.81–1.28) 2,885 (1 RCT) (59); very low
North America 122 136 RR 0.90 (0.67–1.19), HR 0.89 (0.65–1.21) 1,394 (1 RCT) (59); very low
Latin America 74 119, 46 [7–84] RR 0.62 (0.42–0.90), NNTp 22 [12–135], 
HR 0.58 (0.39–0.86)
1,081 (1 RCT) (59); very low‡
Africa 123 137 RR 0.90 (0.49–1.64), HR 0.86 (0.45–1.65) 313 (1 RCT) (59); very low
Asia 79 111 RR 0.71 (0.51–1.00), HR 0.70 (0.49–1.01) 1,347 (1 RCT) (59); very low
HbA1c
<8.5% 100 130, 30 [10–49] RR 0.77 (0.65–0.91), NNTp 34 [20–97], HR 
0.76 (0.64–0.90)
4,819 (1 RCT) (59); low‡
≥8.5% 114 101 RR 1.13 (0.87–1.47), HR 1.14 (0.86–1.50) 2,201 (1 RCT) (59); very low
BMI (kg/m2)
<30 99 132, 33 [10–57] RR 0.75 (0.61–0.91), NNTp 30 [18–99], HR 
0.74 (0.60–0.91)
3,399 (1 RCT) (59); very low‡
≥30 110 110 RR 1.00 (0.82–1.21), HR 0.98 (0.80–1.21) 3,621 (1 RCT) (59); low
SBP/DBP (mmHg)
≥140/≥90 120 140 RR 0.86 (0.70–1.05), HR 0.83 (0.66–1.03) 2,714 (1 RCT) (59); very low
<140/<90 95 108 RR 0.88 (0.73–1.06), HR 0.89 (0.73–1.08) 4,306 (1 RCT) (59); low
Estimated glomerular filtration rate (mL/min/1.73m2)
≥90 97 90 RR 1.08 (0.77–1.51), HR 1.10 (0.77–1.57) 1,538 (1 RCT) (59); very low
60–90 87 112, 25 [4–46] RR 0.78 (0.64–0.95), NNTp 40 [22–251], 
HR 0.76 (0.61–0.94)
3,663 (1 RCT) (59); very low‡
≤60 145 163 RR 0.89 (0.71–1.12), HR 0.88 (0.69–1.13) 1,819 (1 RCT) (59); very low
Urine albumin-to-creatinine ratio (mg/g)
<30 86 97 RR 0.89 (0.73–1.09), HR 0.89 (0.72–1.10) 4,171 (1 RCT) (59); very low
30–300 118 133 RR 0.89 (0.70–1.13), HR 0.89 (0.69–1.16) 2,013 (1 RCT) (59); very low




102 89 RR 1.15 (0.76–1.74), HR 1.15 (0.74–1.78) 960 (1 RCT) (59); very low
Only coronary artery 
disease
96 113 RR 0.84 (0.70–1.02), HR 0.83 (0.68–1.02) 4,072 (1 RCT) (59); low
Only peripheral artery 
disease
61 63 RR 0.97 (0.50–1.88), HR 0.94 (0.47–1.88) 603 (1 RCT) (59); very low
2 or 3 high cardiovascular 
risk categories
156 193 RR 0.81 (0.63–1.03), HR 0.79 (0.61–1.04) 1,329 (1 RCT) (59); very low
Metformin
No 119 155, 36 [2–71] RR 0.77 (0.60–0.97), NNTp 27 [14–459], 
HR 0.72 (0.56–0.94)
1,827 (1 RCT) (59); very low‡
Yes 99 109 RR 0.91 (0.77–1.08), HR 0.92 (0.77–1.10) 5,193 (1 RCT) (59); low
Sulfonylurea
No 110 129 RR 0.86 (0.72–1.02), HR 0.85 (0.70–1.02) 4,014 (1 RCT) (59); low
Yes 97 110 RR 0.88 (0.71–1.10), HR 0.87 (0.69–1.11) 3,006 (1 RCT) (59); very low
Insulin
No 92 117, 24 [3–46] RR 0.79 (0.65–0.97), NNTp 41 [22–341], 
HR 0.79 (0.64–0.97)
3,633 (1 RCT) (59); very low‡
Yes 118 125 RR 0.94 (0.78–1.14), HR 0.93 (0.75–1.13) 3,387 (1 RCT) (59); low
Thiazolidinediones
No 104 121, 17 [1–34] RR 0.86 (0.74–0.99), NNTp 58 [30–866], 
HR 0.85 (0.73–0.98)
6,721 (1 RCT) (59); low‡
Yes 116 109 RR 1.07 (0.54–2.10), HR 1.13 (0.55–2.31) 2,99 (1 RCT) (59); very low
DPP-4 inhibitor
No 102 123, 21 [4–38] RR 0.83 (0.71–0.96), NNTp 47 [26–231], 
HR 0.81 (0.70–0.95)
6,224 (1 RCT) (59); low‡
Yes 127 105 RR 1.21 (0.80–1.83), HR 1.27 (0.82–1.98) 796 (1 RCT) (59); very low
Statins/ezetimibe
No 103 129 RR 0.80 (0.60–1.06), HR 0.79 (0.59–1.07) 1,580 (1 RCT) (59); very low
Yes 105 118 RR 0.89 (0.76–1.04), HR 0.88 (0.74–1.04) 5,440 (1 RCT) (59); low
Antihypertensives
No 87 98 RR 0.89 (0.44–1.78), HR 0.94 (0.45–1.95) 353 (1 RCT) (59); very low
Yes 105 122 RR 0.86 (0.75–1.00) 6,667 (1 RCT) (59); low
ACE inhibitor/ARB
No 102 131 RR 0.78 (0.58–1.06), HR 0.77 (0.56–1.07) 1,354 (1 RCT) (59); very low
Yes 105 118 RR 0.89 (0.76–1.04), HR 0.88 (0.75–1.04) 5,666 (1 RCT) (59); low
Calcium channel blockers
No 102 116 RR 0.88 (0.74–1.04), HR 0.87 (0.73–1.05) 4,703 (1 RCT) (59); low
Yes 111 131 RR 0.85 (0.67–1.06), HR 0.83 (0.65–1.06) 2,317 (1 RCT) (59); very low
Beta blockers
No 97 108 RR 0.90 (0.71–1.16), HR 0.90 (0.70–1.17) 2,466 (1 RCT) (59); very low
Yes 108 128 RR 0.85 (0.72–1.00), HR 0.83 (0.70–1.00) 4,554 (1 RCT) (59); very low
Diuretics
No 86 103 RR 0.84 (0.69–1.03), HR 0.83 (0.67–1.02) 3,985 (1 RCT) (59); very low
Yes 128 146 RR 0.88 (0.73–1.06), HR 0.88 (0.71–1.07) 3,035 (1 RCT) (59); very low
Acetylsalicylic acid
No 109 131 RR 0.83 (0.60–1.14), HR 0.80 (0.57–1.12) 1,217 (1 RCT) (59); very low
Yes 104 119 RR 0.87 (0.75–1.02), HR 0.87 (0.74–1.02) 5,803 (1 RCT) (59); low
Population: adults with uncontrolled type 2 diabetes (7%≤ HbA1c ≤10%) and established cardiovascular disease; settings: outpatient; intervention: empagliflozin, any dose, orally, once daily; comparator: placebo. ‡, favors 
empagliflozin. HbA1c, hemoglobin A1c; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BMI, body mass index; CI, confidence interval; DBP, diastolic blood pressure; DPP-4, dipeptidyl peptidase-4; 
GRADE, Grading of Recommendations Assessment, Development and Evaluation; HR, hazard ratio; NNTp, number needed to treat to prevent an outcome in one patient; RCT, randomized controlled trial; RR, relative risk; SBP, 
systolic blood pressure.
Table S2 Adverse effects after empagliflozin versus placebo in subgroups of adults with type 2 diabetes
Outcomes Risk with intervention per 1,000 
Risk with comparator per 1,000, attributable avoided events per 1,000 
treated [95% CI]
Relative measure of association (95% CI)
Number of participants (studies); quality of evidence 
(GRADE)
Urinary tract infection 180 181 RR 0.99 (0.89–1.10) 7,020 (1 RCT) (59); low
Male patients 105* 94* RR 1.12 (0.93–1.33) 5,016 (1 RCT) (59); low
Female patients 364* 406* RR 0.90 (0.80–1.01) 2,004 (1 RCT) (59); low
Complicated urinary tract infection 17 18 RR 1.00 (0.69–1.44) 7,020 (1 RCT) (59); very low
Genital infection 64 18, 46 [37–55] RR 3.57 (2.59–4.91), NNT 22 [18–27] 7,020 (1 RCT) (59); low§
Male patients 50* 15*, 35 [26–44] RR 3.34 (2.21–5.07), NNT 29 [23–39] 5,016 (1 RCT) (59); very low§
Female patients 100* 26*, 74 [54–94] RR 3.84 (2.34–6.30), NNT 14 [11–19] 2,004 (1 RCT) (59); very low§
Volume depletion 51 49 RR 1.03 (0.83–1.28) 7,020 (1 RCT) (59); very low
Acute renal failure 52 66, 14 [2–26] RR 0.79 (0.65–0.96), NNTp 72 [39–500] 7,020 (1 RCT) (59); very low‡
Acute kidney injury 10 16, 6 [0–12] RR 0.61 (0.39–0.93), NNTp 160 [83–2,123] 7,020 (1 RCT) (59); very low‡
Thirst 31 3, 29 [15–43] RR 7.39 (1.43–38.17), NNT 34 [23–67] 1,150 (2 RCTs) (7,31,50,51,62); low§
Pollakiuria 50 21, 30 [12–48] RR 2.08 (1.06–4.08), NNT 33 [21–83] 1,533 (5 RCTs) (7,11,50,51,62,77,78,81-83); low§
Diabetic ketoacidosis 1 0 RR 1.99 (0.22–17.80) 7,020 (1 RCT) (59); very low
Thromboembolic event 6 9 RR 0.75 (0.42–1.31) 7,020 (1 RCT) (59); very low
Bone fracture 38 39 RR 0.98 (0.76–1.25) 7,020 (1 RCT) (59); very low
Sudden death 11 16 RR 0.69 (0.46–1.05) 7,020 (1 RCT) (59); very low
Fatal worsening of heart failure 2 8, 6 [2–10] RR 0.29 (0.14–0.60), NNTp 173 [103–527] 7,020 (1 RCT) (59); very low‡
Fatal acute myocardial infarction 3 5 RR 0.68 (0.31–1.48) 7,020 (1 RCT) (59); very low
Fatal stroke 3 5 RR 0.72 (0.34–1.56) 7,020 (1 RCT) (59); very low
Fatal cardiogenic shock 1 1 RR 0.50 (0.10–2.46) 7,020 (1 RCT) (59); very low
Hypertension 15 31 RR 0.42 (0.22–0.81) 3,393 (6 RCTs) (40,53-56,63-67,77,78); low‡
Acute kidney injury 21 36 RR 0.59 (0.34–1.04) 1,819 (1 RCT) (58); very low
Acute renal failure 112 143 RR 0.78 (0.61–1.01) 1,819 (1 RCT) (58); very low
Bone fracture 47 53 RR 0.89 (0.59–1.36) 1,819 (1 RCT) (58); very low
Complicated urinary tract infection 31 28 RR 1.09 (0.62–1.92) 1,819 (1 RCT) (58); very low
Confirmed hypoglycemic adverse event 323 384, 61 [14–108] RR 0.84 (0.74–0.96), NNTp 16 [9–69] 1,819 (1 RCT) (58); very low‡
Cystitis 0 0 RR inestimable 1,819 (1 RCT) (58); very low
Cystitis bacterial 0 0 RR inestimable 1,819 (1 RCT) (58); very low
Cystitis glandularis 0 0 RR inestimable 1,819 (1 RCT) (58); very low
Cystitis hemorrhagic 0 0 RR inestimable 1,819 (1 RCT) (58); very low
Diabetic ketoacidosis 2 2 RR 1.00 (0.09–11.02) 1,819 (1 RCT) (58); very low
Escherichia urinary tract infection 0 2 RR 0.17 (0.01–4.10) 1,819 (1 RCT) (58); very low
Genital infection 53 16, 50 [52–20] RR 3.21 (1.66–6.20), NNT 28 [50–19] 1,819 (1 RCT) (58); very low§
Hyperkalemia 39 69, 19 [7–53] RR 0.56 (0.37–0.84), NNTp 33 [19–134] 1,819 (1 RCT) (58); very low‡
Hypoglycemic adverse event requiring 
assistance
19 30 RR 0.64 (0.35–1.18) 1,819 (1 RCT) (58); very low
Kidney infection 1 3 RR 0.25 (0.02–2.76) 1,819 (1 RCT) (58); very low
Nephritis 0 0 RR inestimable 1,819 (1 RCT) (58); very low
Pyelonephritis 3 3 RR 1.00 (0.18–5.45) 1,819 (1 RCT) (58); very low
Pyelonephritis acute 3 2 RR 2.00 (0.22–17.88) 1,819 (1 RCT) (58); very low
Pyelonephritis chronic 4 7 RR 0.63 (0.17–2.32) 1,819 (1 RCT) (58); very low
Thromboembolic event 11 12 RR 0.93 (0.37–2.32) 1,819 (1 RCT) (58); very low
Urinary tract infection 229 217 RR 1.05 (0.88–1.27) 1,819 (1 RCT) (58); low
Urinary tract infection, fungal 2 0 RR 2.51 (0.12–52.12) 1,819 (1 RCT) (58); very low
Urinary tract infection, pseudomonal 0 0 RR inestimable 1,819 (1 RCT) (58); very low
Urosepsis 7 3 RR 2.25 (0.49–10.40), Peto OR 3.13 (1.10–
8.95) (68)
1,819 (1 RCT) (58); very low§
Volume depletion 67 81 RR 0.83 (0.59–1.16) 1,819 (1 RCT) (58); very low
Acute kidney injury 5 9 RR 0.63 (0.32–1.24) 5,199 (1 RCT) (58); very low
Acute renal failure 32 39 RR 0.80 (0.60–1.08) 5,199 (1 RCT) (58); very low
Bone fracture 35 34 RR 1.03 (0.76–1.39) 5,199 (1 RCT) (58); very low
Complicated urinary tract infection 13 14 RR 0.93 (0.57–1.52) 5,199 (1 RCT) (58); very low
Confirmed hypoglycemic adverse event 263 242 RR 1.09 (0.98–1.20) 5,199 (1 RCT) (58); low
Cystitis 0 1 RR 0.10 (0.00–2.07) 5,199 (1 RCT) (58); very low
Cystitis, bacterial 0 1 RR 0.17 (0.01–4.07) 5,199 (1 RCT) (58); very low
Cystitis glandularis 0 0 RR 1.49 (0.06–36.59) 5,199 (1 RCT) (58); very low
Cystitis, hemorrhagic 0 1 RR 0.17 (0.01–4.07) 5,199 (1 RCT) (58); very low
Diabetic ketoacidosis 1 0 RR 2.49 (0.12–51.75) 5,199 (1 RCT) (58); very low
Escherichia urinary tract infection 0 0 RR inestimable 5,199 (1 RCT) (58); very low
Genital infection 68 19, 26 [60–39] RR 3.68 (2.56–5.30), NNT 20 [26–17] 5,199 (1 RCT) (58); very low§
Hyperkalemia 13 21 RR 0.64 (0.41–0.98) 5,199 (1 RCT) (58); very low‡
Hypoglycemic adverse event requiring 
assistance
12 10 RR 1.10 (0.64–1.92) 5,199 (1 RCT) (58); very low
Kidney infection 1 0 RR 3.48 (0.18–67.33) 5,199 (1 RCT) (58); very low
Nephritis 0 0 RR 1.49 (0.06–36.59) 5,199 (1 RCT) (58); very low
Pyelonephritis 3 1 RR 2.24 (0.48–10.34) 5,199 (1 RCT) (58); very low
Pyelonephritis, acute 1 3 RR 0.40 (0.11–1.48) 5,199 (1 RCT) (58); very low
Pyelonephritis, chronic 1 3 RR 0.41 (0.13–1.36) 5,199 (1 RCT) (58); very low
Thromboembolic event 5 8 RR 0.65 (0.32–1.33) 5,199 (1 RCT) (58); very low
Urinary tract infection 162 169 RR 0.96 (0.85–1.10) 5,199 (1 RCT) (58); low
Urinary tract infection, fungal 0 0 RR 1.49 (0.06–36.59) 5,199 (1 RCT) (58); very low
Urinary tract infection, pseudomonal 0 0 RR 1.49 (0.06–36.59) 5,199 (1 RCT) (58); very low
Volume depletion 45 38 RR 1.19 (0.90–1.58) 5,199 (1 RCT) (58); very low
Large intestine polyp 2 0 Peto OR 7.36 (1.27–42.54) 4,678 (1 RCT) (68); very low§
Bladder cancer 2 0 Peto OR 7.37 (1.28–42.59) 4,675 (1 RCT) (68); very low§
Balanitis candida 51 0 Peto OR 73.44 (9.20–586.20) 417 (1 RCT) (64); very low§
Population: adults with uncontrolled type 2 diabetes (7%≤ HbA1c ≤10%); settings: outpatient; intervention: empagliflozin, any dose, orally, once daily; comparator: placebo. ‡, favors empagliflozin; §, favors placebo; *, risk with intervention and control do not 
sum due to differences in the number of women and men in the trial. HbA1c, hemoglobin A1c; CI, confidence interval; GRADE, Grading of Recommendations Assessment, Development and Evaluation; NNT, number needed to treat; NNTp, number needed to 
treat to prevent an outcome in one patient; OR, odds ratio; RCT, randomized controlled trial; RR, relative risk.
Table S3 Post-marketing reports search results for empagliflozin 
Drug # Reports Adverse events Reports by gender Reports by age
Empagliflozin 1,969 Diabetic ketoacidosis [205], fungal infection [173], weight decreased [156], ketoacidosis [95], 
blood glucose increased [92], pollakiuria [92], dizziness [91], dehydration [76], nausea [73], 
vomiting [69], urinary tract infection [65], diarrhea [60], glycosylated hemoglobin increased [51], 
rash [49], fatigue [43], back pain [42], headache [36], malaise [36], asthenia [35], drug ineffective 
[34]
Female [928], male [873] 20+ [1,107], <20 [7]
Metformin hydrochloride 34,605 Lactic acidosis [6,754], diarrhea [3,774], renal failure acute [3,754], blood glucose increased 
[3,005], hypoglycemia [2,166], vomiting [2,140], nausea [1,994], metabolic acidosis [1,631], 
hypotension [1,191], renal failure [1,169], drug ineffective [1,105], therapeutic agent toxicity 
[1,012], malaise [1,010], abdominal pain [959], dehydration [925], dyspnea [925], completed 
suicide [889], asthenia [860], blood creatinine increased [835], dizziness [825]
Female [17,969], male 
[13,371]
20+ [23,180], <20 
[531]
Glimepiride 3,207 Hypoglycemia [675], blood glucose increased [211], hypoglycemic coma [142], renal failure 
acute [126], loss of consciousness [114], drug interaction [108], nausea [98], malaise 
[97], hyperglycemia [90], asthenia [89], blood glucose decreased [87], depressed level of 
consciousness [85], renal failure [83], dizziness [79], drug ineffective [77], dyspnea [75], vomiting 
[72], pyrexia [69], confusional state [68], medication error [68]
Male [1,534], female [1,355] 20+ [2,367], <20 [41]
Linagliptin 4,627 Pancreatitis [328], blood glucose increased [270], nausea [216], rash [178], hypoglycemia [163], 
drug ineffective [140], diarrhea [137], dizziness [127], abdominal pain [125], vomiting [110], 
urticaria [108], pruritus [92], headache [91], abdominal pain upper [84], glycosylated hemoglobin 
increased [84], renal failure acute [79], pancreatitis acute [78], weight decreased [76], dyspnea 
[72], pneumonia [71]
Female [2,140], male [2,075] 20+ [2,938], <20 [6]
Sitagliptin phosphate 30,135 Pancreatitis [2,459], blood glucose increased [1,960], pancreatic carcinoma [1,604], drug 
ineffective [1,487], diarrhea [1,175], nausea [1,175], hypoglycemia [1,163], headache [1,037], 
death [888], dizziness [860], rash [820], weight decreased [693], inappropriate schedule of drug 
administration [692], vomiting [670], edema peripheral [621], abdominal pain [620], constipation 
[620], dyspnea [584], hypertension [584], renal failure acute [575]
Female [13,727], male 
[12,378]
20+ [16,317], <20 [45]
Data from https://www.pharmapendium.com. Retrieved March 30, 2017.
Table S4 Adverse effects reported in drug labels 
Adverse effects Glimepiride Metformin Sitagliptin Linagliptin Empagliflozin




Anaphylactic reactions Yes Yes Yes
Angioedema Yes Yes Yes
Anorexia Yes
Aplastic anemia Yes





Bullous rash Yes Yes
Candidiasis Yes














Elevated hepatic enzymes Yes Yes Yes
Erythema Yes
Exfoliative dermatitis Yes Yes
Flatulence Yes
Flushing Yes Yes











Increased urinary frequency Yes
























Pruritus Yes Yes Yes
Purpura Yes
Rash (unspecified) Yes Yes Yes
Renal failure (unspecified) Yes Yes
Secondary failure Yes
SIADH Yes




Urticaria Yes Yes Yes
Vaginitis Yes
Vasculitis Yes Yes
Vitamin B12 deficiency Yes
Weakness Yes
Weight gain Yes Yes
Weight loss Yes Yes
Hyperhidrosis Yes
Vomiting Yes Yes
Nausea Yes Yes Yes Yes
Balanitis Yes
Report from Elsevier Clinical Pharmacology drug database: http://www.clinicalpharmacology-ip.com/default.aspx. SIADH, syndrome of 
inappropriate antidiuretic hormone secretion. 
